Findings to be Presented at ARVO 2025 Alongside
Additional Work in Myopia Management and Contact Lens Comfort
ROCHESTER, N.Y., MAY 1, 2025—New research from a CooperVision and University of Rochester Flaum Eye Institute team, in collaboration with the Instituto de Optica “Daza de Valdés” (IO-CSIC), has identified a novel marker for presbyopic accommodation that may drive future category innovation. The paper will be presented at the ARVO 2025 Annual Meeting, which takes place in Salt Lake City, Utah, on Wednesday, May 7.
OCT-Based Marker for Accommodative Effort in Presbyopes1 explores how both anterior segment and crystalline lens geometry change in relation to accommodative demand, specifically among emmetropic and myopic presbyopes with different correction needs. Using 3D optical coherence tomography (OCT), the investigators observed measurable geometric alterations across the range of subjects and presbyopia stages. Some focus ability, even though diminished, remained in presbyopes. Crystalline lens thickness emerged as a key marker for assessing focusing effort in such individuals, particularly in myopes.
“We believe this is the first in vivo study to show the evolution of physiological response of the crystalline lens as adults age,” said Percy Lazon de la Jara, Director of Research Programs for CooperVision and a paper co-author. “CooperVision’s deep commitment to advancing ocular science and care means evaluating the entire eye, including how it changes from presbyopia onset through stabilization. This latest work—employing a remarkable application of OCT to uncover previously unavailable insights¬—will help map optical corrections that could be incorporated into future presbyopia correction methods and devices.”
Presbyopes today make up about one-third of the world’s population, affecting those in their mid-40s.2 CooperVision manufactures a range of contact lenses for correcting the condition, including MyDay® multifocal and clariti® 1 day multifocal 3 Add.* Both feature the CooperVision Binocular Progressive System®, an innovation that caters to all levels of presbyopia to provide optimal visual acuity at all distances.3,4 The innovative technology system offers the additional advantage of a simple fitting process3 to make it easy for eye care professionals to fit patients with the right lens.
CooperVision scientists and research partners will also share additional foundational and clinical research during ARVO 2025, which is attended by thousands of ocular scientists, clinicians, educators, and students. Among several posters are topics relating to myopia management (e.g., Myopia Control Efficacy and Choroid Response with Dual-Focus Contact Lenses in Chinese Children)5 and contact lens comfort (e.g., Characterizing Sensory Adaptation in Contact Lens Wearers Experiencing Ocular Discomfort).6
For more information about ARVO 2025, visit https://www.arvo.org/annual-meeting/.
###
* clariti® 1 day multifocal 3 Add is not available in all markets.
References
1 Marcos S. et al. OCT-based marker for accommodative effort in presbyopes. ARVO 2025 poster presentation.
2 Wolffsohn J, Berkow D, et al. BCLA CLEAR Presbyopia: Evaluation and diagnosis. CLAE. 2024; 47(4): 102156.
3 CVI data on file, 2024.
4 CVI data on file, 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with ratings from 85 to 89 out of 100; n=90 habitual multifocal contact lens wearers.
5 Arumugam B et al. Myopia control efficacy and choroid response with dual-focus contact lenses in Chinese children. ARVO 2025 poster presentation.
6 Situ P et al. Characterizing sensory adaptation in contact lens wearers experience in ocular discomfort. ARVO 2025 poster presentation.
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Mike McDougall, FAAO, APR, Fellow PRSA
McDougall Communications for CooperVision